Why this trial matters: First global Phase III success in a disease with no approved targeted therapy Could change management of systemic symptoms and glandular dysfunction Gene Therapy Phase III in Epidermolysis Bullosa Shows Healing Benefit A Phase III gene therapy trial for epidermolysis bullosa (EB) demonstrated significantly better wound healing, less pain, and reduced itching compared with standard care, and the therapy earned FDA approval in 2025 a major advance for this previously untreatable genetic skin disorder
6.5.2 Alzheimers disease Alzheimers disease is the most prevalent neurodegenerative illness, with several pathogenic mechanisms contributing to its development (Twarowski and Herbet, 2023)
Glow GHK-CU, like most peptides, is sensitive to temperature and moisture
MIC B12 (methionine, inositol, choline, and vitamin B12) Break down fats and increase metabolism Promote weight loss by boosting metabolism and reducing appetite B12 is involved in the production of serotonin, which may help regulate your mood Enhances the benefits of Semaglutide and Tirzepatide Most patients see an increased energy and suppressed appetite within 2-3 weeks after starting MIC B12 injections Contact us
Characterization of the gastric mycobiome in 22 samples of gastric cancer and normal adjacent tissue and 11 non-cancerous normal tissue samples demonstrated that fungi exist in non-virulent morphotypes in normal cells, whereas they switch to virulent morphotypes in tumor microenvironments [14]